CRSP · CRISPR Therapeutics AG
$58.12
-1.69 (-2.83%)
At close · Aug 20
Market Cap
$5.48B
Shares
96.69M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Julianne Bruno | Chief Operating Officer | Resigned | 2025-03-26 |
| Christian Rommel, Ph.D. | members of the Company's Board of Directors | Appointed | 2024-06-03 |
| Sandesh Mahatme, LL.M. | members of the Company's Board of Directors | Appointed | 2024-06-03 |
| Samarth Kulkarni, Ph.D. | chairman of the Company's Board of Directors | Appointed | 2024-06-03 |
| Julianne Bruno | Chief Operating Officer | Appointed | 2024-05-23 |
| Phuong Khanh Morrow | Chief Medical Officer | Resigned | 2023-12-19 |
| Samarth Kulkarni, Ph.D. | Chairman of the Board | Appointed | 2023-09-07 |
| Rodger Novak, M.D. | director | Resigned | 2023-09-07 |
| Rodger Novak, M.D. | Chairman of the Board of Directors | Resigned | 2023-09-07 |
| Bradley Bolzon, Ph.D. | director | Resigned | 2023-03-29 |
| Brendan Smith | Executive Vice President and Chief Financial Officer | Resigned | 2023-03-14 |
| Raju Prasad, Ph.D. | principal accounting officer | Appointed | 2023-03-14 |
| Raju Prasad, Ph.D. | Chief Financial Officer | Appointed | 2023-03-14 |
| Lawrence O. Klein | Chief Operating Officer | Resigned | 2022-10-27 |
| Maria Fardis | member of the Company's Board of Directors | Appointed | 2022-06-13 |
| Tony W. Ho | Executive Vice President, Research and Development | Terminated | 2021-12-20 |
| Michael Tomsicek | Chief Financial Officer | Retired | 2021-10-14 |
| Michael Tomsicek | Senior Vice President and Chief Financial Officer | Retired | 2021-10-14 |
| Brendan Smith | Senior Vice President and Chief Financial Officer | Appointed | 2021-10-14 |
Key facts
CIK
1674416
CUSIP
H17182108
13F (30d)
463 filings
455 filers
Visit website
Investor relations